AZTAAzenta Inc.

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

Azenta’s second quarter showed strong momentum, with results surpassing Wall Street’s expectations for both revenue and earnings. Management attributed this outperformance to robust growth in its biorepositories and consumables and instruments (C&I) segments, which are recurring revenue businesses, alongside improved execution in Multiomics, particularly in Europe and China. CEO John Marotta highlighted, “Revenue exceeded our outlook, profitability improved sequentially and Multiomics delivered

Recurring revenue tops 50% as automation investments drive operational progress.

Azenta, Inc. recently reported third-quarter 2026 results showing revenue of US$161.18 million versus US$143.86 million a year earlier, swung to a quarterly net income of US$2.46 million from a net loss, modestly raised full-year revenue guidance to US$613–US$618 million, and completed a US$50 million repurchase of 2,300,000 shares. While the company still reported a higher net loss of US$173.77 million over the first nine months of fiscal 2026 than a year earlier, the combination of...

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI enthusiasm […]

Strong multi-omics performance in Europe and China offsets capital equipment softness, while company completes B Medical divestiture and boosts shareholder returns.

Azenta (NASDAQ:AZTA) reported third-quarter fiscal 2026 revenue that exceeded its outlook, as growth in recurring-revenue businesses and improved Multiomics performance helped offset continued unevenness in capital equipment markets. Total revenue was $161 million, up 12% on a reported basis and 9%

Moby summary of Azenta, Inc.'s Q3 2026 earnings call

Life sciences company Azenta (NASDAQ:AZTA) announced better-than-expected revenue in Q2 CY2026, with sales up 12% year on year to $161.2 million. Its non-GAAP profit of $0.16 per share was 60% above analysts’ consensus estimates.

(Bloomberg) -- SpaceX’s first earnings report following its blockbuster initial public offering is one of the most anticipated events of the summer on Wall Street. Whether it’ll give investors a reason to buy the sinking stock is another matter.Most Read from BloombergBeer Dynasty Families Sell €731 Million Stake in AB InBevApple’s New CEO Taps Retired Hardware Executive for Management TeamTaco Bell Met With Michigan on Parasite Weeks Before RecallMamdani Dismisses Business Leaders Advising NYC’

Azenta stock is coming off a difficult five year stretch, yet the valuation checks send a more balanced signal. The Discounted Cash Flow (DCF) intrinsic value estimate sits close to the current share price, while the broader metrics and long term share price performance give investors more to weigh up. Azenta shareholders have seen the stock decline 66.9% over the past five years, which puts extra focus on whether the current price now reflects a reset of expectations or lingering...

Life sciences company Azenta (NASDAQ:AZTA) will be reporting results this Tuesday after the bell. Here’s what investors should know.

Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.